Advance progress of radionuclide target tumor therapy

Radionuclide internal therapy is an important method for tumor treatment. Radioimmunotherapy (RIT) and peptide receptor radionuclide therapy (PPRT) are two major strategies for tumor therapy by targeting antigen or receptor over-expressed in tumor cells with radionuclide labeled monoclonal antibody or peptide separately. RIT and PPRT have been dramatically developed with several agents have been used in clinic and more are underwent clinic or pre-clinic trial. The radionuclide therapy will play more important role in tumor therapy with the more specific target been selected and improvement of the methods. Key words: Tumor; Antibodies, monoclonal; Radionuclidetherapy; Radioimmunotherapy